Venous thromboembolism in oncology

Experimental Oncology

Volumn 26, Issue 1, 2004, Pages 11-14

  Falanga, Anna ^a   Vignoli, Alfonso ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Acquired thrombophilia; Cancer; Low molecular weight heparin; Thromboprophylaxis; Thrombosis

Indexed keywords

DALTEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; TAMOXIFEN; WARFARIN;

BLOOD CLOTTING; CANCER MORTALITY; CANCER PATIENT; CLINICAL FEATURE; DISEASE ASSOCIATION; HEMOSTASIS; HUMAN; IDIOPATHIC DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; OCCULT CANCER; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; ARTICLE; CENTRAL VENOUS CATHETER; DOSE RESPONSE; DRUG EFFECT; NEOPLASM; ONCOLOGY; PROPHYLAXIS;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; HUMANS; NEOPLASMS; VENOUS THROMBOSIS;

EID: 1942473857     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6-12.
2. Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
3. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993; 70: 343-50.
4. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28, Suppl. 3: 50-60.
5. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999; 25: 173-82.
6. Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer. Semin Thromb Hemost 1999; 25: 131-6.
7. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep vein thrombosis and the incidence of susequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
8. Rickles FR, Falanga A. Molecular bases for the relationship between thrombosis and cancer. Thromb Res 2001; 102: 215V-24.
9. Kakkar AK, Williamson RCN. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25: 239-43.
10. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A et al. Low molecular weight heparin started before surgery as prophylaxis against deep venous thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501.
11. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Nieto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. The ENOXACAN II Investigators. N Engl J Med 2002; 346: 975-80.
12. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 1999; 25: 147-55.
13. Bern MM, Lokich JJ, Wallach SR, Bothe AJr, Benotti PN, Arkin CF, Greco FA, Hoberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423-8.
14. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
15. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, Arnold A, Finday B, Skillings JR, Bromwell VH et al. The thrombogenic effect of anticancer drug therapy in women with second stage breast cancer. N Engl J Med 1988; 318: 404-7.
16. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bromwell V, Pritchard KI, Steward D et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
17. Fisher B, Costantino JP, Wickerman DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
18. von Tempelhoff GF, Dietrich M, Niemann F, Scheneider D Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456-61.
19. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 2000; 89: 640-6.
20. Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D, Metz KA, Leder LD, Cyrus C, Groth S et al. Deep venous thrombosis and pulmonary artery embolism in high grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54: 186-94.
21. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.